Subtype
Malignant Pharyngeal Neoplasm
CI-CAN-00003219Explore in graph →
411 active trials1 approved drugs2 evidence items
- NCIt
- C7545
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003219Explore in graph →
Clinical trials
1,255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (112)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05020925 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03668730 | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04992988 | Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial | unknown | Phase 2 | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT04539600 | Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer | unknown | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04955886 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 14 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03904225 | Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis | unknown | Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04917770 | The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 28 | West China HospitalOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT04769076 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT02636231 | Endostar for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03558035 | New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma | unknown | Phase 2 | 96 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03915132 | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 47 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04627961 | A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 33 | National University Hospital, SingaporeOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03129412 | Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions | unknown | Phase 2 | 64 | Zhejiang Cancer HospitalOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04553510 | Treatment of Bevacizumab Followed by Steroid in RN | unknown | Phase 2 | 86 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04547088 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04548271 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04534855 | A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 0 | Sep 1, 2020 | clinicaltrials |
| NCT03648697 | EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Aug 11, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04447326 | Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma | unknown | Phase 2 | 106 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Jun 25, 2020 | clinicaltrials |
| NCT04447612 | Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 118 | The University of Hong KongOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT04421469 | Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC | unknown | Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04319471 | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 70 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2020 | clinicaltrials |
| NCT04296747 | Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer | unknown | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT03923842 | Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours(Dern) | unknown | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04222543 | Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging(PIVOT) | unknown | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04220528 | Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC | unknown | Phase 2 | 129 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03020329 | Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04015661 | Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC | unknown | Phase 2 | 92 | Fuzhou General HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT03932266 | Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma | unknown | Phase 2 | 73 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT03890185 | Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC | unknown | Phase 2 | 108 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT03557112 | By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC | unknown | Phase 2 | 180 | Guiyang Medical UniversityOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT03701451 | Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Wei JiangOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT03639467 | Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03666221 | Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 67 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 11, 2018 | clinicaltrials |
| NCT02507154 | Reactivating NK Cells in Treating Refractory Head and Neck Cancer(NKEXPHNC) | unknown | Phase 1 / Phase 2 | 31 | National University Hospital, SingaporeOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT03612219 | Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma | unknown | Phase 2 | 240 | Wei JiangOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03578575 | To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | China Medical University HospitalOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03130270 | Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma | unknown | Phase 2 | 29 | Guilin Medical University, ChinaOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT02590133 | A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC | unknown | Phase 2 | 328 | Yun-fei XiaOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT03344068 | Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 408 | Sun Yat-sen UniversityOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT03290820 | Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients | unknown | Phase 2 | 184 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT03213587 | Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | unknown | Phase 2 | 51 | Zhejiang Cancer HospitalOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT03210389 | A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2017 | clinicaltrials |
| NCT03158324 | Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 | unknown | Phase 2 | 52 | National University Hospital, SingaporeOTHER | 1 | Jun 15, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT03058432 | Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 122 | Zhejiang Cancer HospitalOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02878889 | A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 2 | 53 | Zhejiang Cancer HospitalOTHER | 1 | Jan 11, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2021source: clinicaltrials